Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. Headquartered in Cambridge, Massachusetts, the company utilizes its proprietary platform to silence disease-causing genes, primarily targeting rare genetic, cardiometabolic, and hepatic infectious diseases. The company's commercial portfolio features several approved RNAi medicines, including Onpattro, Givlaari, Oxlumo, and Amvuttra, which address high unmet medical needs in genetically defined patient populations. Alnylam operates globally, managing both in-house drug development and direct commercialization efforts. In addition to its proprietary pipeline, the company leverages strategic partnerships with major pharmaceutical companies to advance clinical programs and expand its international market reach. By translating foundational RNAi science into a programmable drug platform, Alnylam has established a leading position in the field of genetic medicine.
